SAGE's Dalzanemdor Fails to Meet Goal in Alzheimer's Disease Study
Shares of Sage Therapeutics, Inc. SAGE were down 4.3% on Oct. 8 after the company announced disappointing top-line data from the phase II LIGHTWAVE study, which evaluated its neuropsychiatric candidate,
Sage Therapeutics Phase 2 LIGHTWAVE Study In Alzheimer's Disease Fails; Stock Down In Pre-Market
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Tuesday said its Phase 2 LIGHTWAVE study to evaluate dalzanemdor in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's Disease (AD) failed to meet the primary goal. The company's shares were down more than 12 percent in pre-market.
Sage Therapeutics stock drops after disappointing Alzheimer's trial results
Sage Therapeutics shares fell as much as 25% in premarket trading after the company announced disappointing topline results from its Phase 2 LIGHTWAVE study of dalzanemdor (SAGE-718) for the treatment of mild cognitive
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
Sage Therapeutics' dalzanemdor failed to show significant results in Phase 2 Alzheimer's study. The company discontinues Alzheimer's development but expects Huntington's data soon. Stock drops 10.7%.
Sage Therapeutics Shares Fall Premarket After Alzheimer's Setback
Shares of Sage, which closed Monday at $6.72, were recently down 12% to $5.89 in premarket trading. Sage said Tuesday it is ending development of dalzanemdor in Alzheimer's disease after the compound didn't show a statistically significant difference versus placebo on the primary outcome measure of cognitive ability in a Phase 2 study in patients with mild cognitive impairment or mild dementia due to the memory-robbing disease.
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer’s Treatment
The biopharmaceutical company isn’t planning further clinical development of dalzanemdor to treat Alzheimer’s.
BioSpace5d
Sage Suffers Third Neuro Stumble in Six Months With Disappointing Mid-Stage Alzheimer’s Readout
Sage has decided to discontinue the development of dalzanemdor in Alzheimer’s disease. A study of the candidate in Huntington ...
bovnews2d
Lightwave Logic Inc (LWLG) Stock: More Strategic Than Meets the Eye
In recent trading, Lightwave Logic Inc (LWLG) stock price has shown some volatility, fluctuating 8.55% over the last five trades and 11.88% over the past 30 trades. This represents a notable shift ...
Sage Therapeutics: With Dalzanemdor As The Last Lifeline, Not Much Hope Left
Sage Therapeutics is a sell due to failure of SAGE-324 in essential tremors and dalzanemdor's poor performance in Parkinson's ...
Lightwave Logic宣布更换会计师事务所
科罗拉多州英格尔伍德 - 专门从事杂项塑料产品的Lightwave Logic, Inc. (NASDAQ:LWLG)公司报告称,其独立注册会计师事务所发生了变更。周一,Morison Cogen LLP辞去了其职务,公司审计委员会已任命Stephano Slack LLC为新的认证会计师。 Morison的辞职于2024年9月30日生效,这并非由于对2023年和2022财年财务报表的任何不利意见 ...
bovnews12d
Lightwave Logic Inc (LWLG) Stock’s -0.37% Decrease This Year: What’s the Story?
On Monday, Lightwave Logic Inc (LWLG) stock saw a decline, ending the day at $2.76 which represents a decrease of $-0.19 or -6.44% from the prior close of $2.95. The stock opened at $2.95 and touched ...
Morningstar3d
Lightwave Logic Inc LWLG
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Lightwave Logic and Polariton to Jointly Showcase Packaged Electro-Optic Polymer Modulators at the European Conference on Optical Communications
Lightwave Logic, Inc. (NASDAQ: LWLG), a technology platform company leveraging its proprietary electro-optic (EO) polymers to ...
阿尔茨海默病候选药物中期试验失败，Sage Therapeutics(SAGE.US)盘前大跌逾10%
智通财经APP获悉，Sage Therapeutics ...